ArticleJournal of clinical virology : the official publication of the Pan American Society for Clinical Virology2026
Characterization of HIV humoral immunity during analytical treatment interruption.
Article in Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
introductionThis study investigated whether HIV binding antibody (Ab) and p24 antigen (Ag) quantitation could detect humoral immune responses or p24 Ag before or following detectable plasma viral load (VL) rebound during antiretroviral therapy interruption (ATI) and provide insights into post-rebound viral replication.
methodsLongitudinal plasma samples collected before and following ATI from 40 participants (485 samples; mean of 12/participant) in the ACTG A5345 study who began antiretroviral therapy during either acute or chronic stages of infection were analyzed using commercial immunoassays to assess HIV Ab and Ag dynamics, including following dissociation of immune complexes for improved Ag detection.
resultsNeither Ab nor Ag levels increased in plasma before VL rebound. However, 75% of participants exhibited increased Ab reactivity concurrent with or shortly after VL rebound, which declined upon ART reinitiation. Participants who were ART-treated early had lower Ab levels at ATI initiation but demonstrated greater fold increases in Ab during ATI than late-treated participants. Two participants who demonstrated post-treatment control of VL showed gradual Ab increases that paralleled intermittent VL elevations. p24 Ag was only detectable after dissociating immune complexes in samples with VL > 10⁴ RNA copies/mL, correlating strongly with VL levels.
conclusionsAlthough antibody levels did not predict viral rebound, tracking their longitudinal changes provided meaningful information about viral replication patterns and immune reactivation during and after rebound, offering a practical tool for monitoring ATI outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.